Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$42600.00
-1050.00 (-2.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $43.9B · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.21T
P/E
15.9x
↓EV/EBITDA
10.7x
↓ROE
5.7%
↑Gross Margin
45.9%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.9%
FCF CAGR
+28.4%
FCF margin
7.1%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.06T · net income $75.70B · FCF $75.68B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1063.15B | $1063.15B | $897.14B | $828.91B | $846.52B |
| Net Income | $75.70B | $75.70B | $61.58B | $47.20B | $38.13B |
| EBITDA | $152.70B | $152.70B | $126.14B | $102.65B | $87.73B |
| EPS | 2672.00 | 2672.00 | 2174.00 | 1666.00 | 1342.00 |
| Gross Margin | 45.9% | 45.9% | 48.5% | 45.4% | 41.3% |
| Operating Margin | 10.4% | 10.4% | 9.8% | 8.0% | 6.2% |
| Net Margin | 7.1% | 7.1% | 6.9% | 5.7% | 4.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.35 | 0.37 | 0.39 |
| Current Ratio | 1.13 | 1.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $75.68B | $75.68B | $-19.95B | $43.93B | $35.72B |
| Returns | |||||
| ROE | 5.7% | 5.7% | 4.9% | 3.9% | 3.3% |
| Valuation | |||||
| P/E | 15.94 | 15.94 | 16.74 | 26.80 | 27.53 |
| EV/EBITDA | 10.73 | 10.73 | 11.29 | 15.67 | 15.92 |
| P/B | 0.91 | 0.91 | 0.82 | 1.05 | 0.90 |
| Growth & Yield | |||||
| Revenue Growth | 18.5% | 18.5% | 8.2% | -2.1% | — |
| EPS Growth | 22.9% | 22.9% | 30.5% | 24.1% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
12.3%
EPS terminal req.
$3780.04
Spread vs growth
10.6%
5Y implied EPS CAGR
11.3%
EPS terminal req.
$4573.85
Spread vs growth
11.6%
10Y implied EPS CAGR
10.7%
EPS terminal req.
$7366.23
Spread vs growth
12.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.6%
Start / end P/E
18.4x → 15.9x
EPS bridge
2174.00 → 2672.00
Residual
-3.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.